Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer
13 nov. 2024 10h57 HE
|
Curium
ST. LOUIS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that its ECLIPSE trial met its primary endpoint. ECLIPSE is a pivotal Phase 3, multi-center,...
Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call
07 nov. 2024 07h05 HE
|
Celcuity Inc.
MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
06 nov. 2024 08h00 HE
|
Barinthus Biotherapeutics
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
Media Advisory and Interview Opportunity: Movember Joins Forces with Jon Montgomery on a Moustache Mission for Men’s Health
01 nov. 2024 05h00 HE
|
Movember Canada
TORONTO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- It’s Movember 1 and Canada’s hairiest campaign is back to raise awareness, education and important funds for men’s health. This year, Olympian and...
Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
17 oct. 2024 16h30 HE
|
Profound Medical Corp.
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer
16 oct. 2024 16h15 HE
|
Profound Medical Corp.
– Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final...
Prostate Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 150+ Companies Working in the Domain
15 oct. 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prostate Cancer Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 150+ Companies Working in the...
Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT
08 oct. 2024 02h45 HE
|
Hofseth Biocare ASA
Ålesund, Norway, 8 October 2024. HBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel...
Préparez-vous au décollage : Movember s'associe à l'une des moustaches les plus reconnaissables du Canada pour s'attaquer à la santé masculine
01 oct. 2024 09h00 HE
|
Movember Canada
TORONTO, 01 oct. 2024 (GLOBE NEWSWIRE) -- Moustaches (Mos) sont de retour à l'occasion de la campagne la plus poilue du Canada, le 1er Novembre! Cette année, Movember est fier de s'associer à...
Get Ready for Liftoff: Movember Joins Forces with One of Canada’s Most Recognizable Moustaches to Take on Men’s Health
01 oct. 2024 09h00 HE
|
Movember Canada
TORONTO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Moustaches (Mos) are back as Canada’s hairiest campaign returns on Movember 1! This year, Movember is proud to be partnering with Olympian and...